Ganymede Bio CEO and co-founder Nathan Clark claims software for biotech is 10 to 20 years behind other industries. He received $12.75 million for his company to provide more choice to pharmaceutical companies.
Ganymede Bio is a cloud infrastructure provider targeting the life sciences and pharmaceutical industries. The startup, which was founded just this year, announced a series A round on Tuesday. Combined with previous seed rounds, the company has raised a total of $15.6 million to secure more clients in the manufacturing and biopharmaceutical space.
Nathan ClarkClark said endpoint news Ganymede seeks to consolidate laboratory and manufacturing hardware (instruments, instruments, etc.) and applications into one biotech and manufacturer-controlled platform.
“I think there are a lot of companies that offer lab integration, but instrument integration is kind of a service. No one has actually commercialized building integration per se, it was a paradigm that really worked for us.
The Series A funding will be used to hire and retain Ganymede’s staff of software engineers, he said. In the near future, the company aims to add more features and work with lab equipment manufacturers on better ways to connect data. We are focused on getting companies to join our platform.
“We’re going to set up AWS and build all the tech there, like we’re starting consumer finance apps and stuff in 2022. I have to go get Ganymede, set up my stuff there, hook up all the lab equipment there,” he said.
Clark said Ganymede has been working with another tech company, Apprentis, on automation efforts for manufacturers. In 2023, we hope to grow the Ganymede customer list.
“We are apprenticing, actually making pharmaceuticals (clients), working with other (clients) making components … we are actively expanding it more directly and We are starting to win some of our own direct large pharma clients.Today our client base is fairly focused on mid- to late-stage biotech.Their scientific research institutes Now, we aim to bring this to the wider market,” Clark said.
The Series A round was led by Caffeinated Capital.
